Document is current
Any future updates will be listed below
-
Authors
Linton, Sophia
Hossenbaccus, Lubnaa
Davis, Abigail
Thiele, Jen
Garvey, Sarah
Botting, Hannah
Steacy, Lisa
Ellis, Anne K.
-
Funding
Funding for this research was provided by:
CAAIF-Miravo Healthcare Research Grant in Allergic Rhinitis or Urticaria
Queen’s University Health Sciences Spear Endowment/Start Memorial Fund
- License Information
-
More Information
Article History
Received: 2 March 2025
Accepted: 14 July 2025
First Online: 18 August 2025
Declarations
:
: Anne Ellis, MD, MSc, FRCPC: In the past 3 years, Dr. Ellis has participated in advisory boards for AstraZeneca, AbbVie Pharma, Agence Unik, Celltrion Pharmaceuticals, GSK, LEO Pharma, Miravo, Novartis, and Sanofi; has been a speaker for ALK Abello, AstraZeneca, COVIS Pharma, GSK, Novartis Pharmaceuticals, Orexo, Regeneron Pharmaceuticals, and Sanofi; has received research grants (through her institution) from ALK Abello, AstraZeneca, Bayer, Novartis Pharmaceuticals, Sanofi (and Opella Healthcare SAS), and Regeneron Pharmaceuticals; and served as an independent consultant to Bayer LLC, ARS, GSK, and Regeneron Pharmaceuticals. The remaining authors have no conflicts of interest to report.
